Sugi Holdings Co.,Ltd. (SGIPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sugi Holdings Co.,Ltd. (SGIPF) trades at $20.40. Sugi Holdings Co. ,Ltd. operates a network of drugstores in Japan, providing pharmaceutical products and healthcare-related services. Market cap: $3.69B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for SGIPF: SGIPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SGIPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SGIPF: 1/1 perspectives are bearish.
How is this calculated? →Sugi Holdings Co.,Ltd. (SGIPF) Healthcare & Pipeline Overview
Sugi Holdings Co.,Ltd., a Japanese drugstore chain, operates approximately 1,483 stores, offering pharmaceutical products, health counseling, and home-visit services. With a market capitalization of $3.69B and a P/E ratio of 14.93, Sugi focuses on community-based healthcare solutions, distinguishing itself through integrated services like elderly care support and medical consulting.
What Is the Investment Thesis for SGIPF?
Sugi Holdings, with a market cap of $3.69B and a P/E ratio of 14.93, presents a compelling investment case based on its established presence in the Japanese drugstore market and its integrated healthcare service offerings. The company's focus on community-based healthcare, including home-visit prescription dispensing and elderly care support, aligns with the growing demand for accessible healthcare solutions in Japan's aging society. A gross margin of 31.6% and a profit margin of 4.3% indicate stable profitability. Growth catalysts include expanding its network of drugstores and enhancing its healthcare service offerings. However, potential risks include increasing competition from other drugstore chains and regulatory changes in the healthcare sector.
Based on FMP financials and quantitative analysis
SGIPF Key Highlights
- Market capitalization of $3.69B reflects the company's established position in the Japanese drugstore market.
- P/E ratio of 14.93 suggests a reasonable valuation compared to its earnings.
- Gross margin of 31.6% indicates efficient cost management in its retail operations.
- Profit margin of 4.3% demonstrates the company's ability to generate profits from its revenue streams.
- Dividend yield of 1.00% provides a modest return to shareholders.
Who Are SGIPF's Competitors?
SGIPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANHGY Mediclinic International plc | $5.49 | +0.00% | $4.05B | 44 |
| ASPHF Ascentage Pharma Group International | $4.53 | +0.00% | $1.69B | 51 |
| DCHPF Dechra Pharmaceuticals PLC | $46.90 | -0.21% | $5.34B | 48 |
| GALNF Galenica AG | $115.00 | +0.00% | $5.73B | 46 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SGIPF's Key Strengths?
- Established presence in the Japanese drugstore market.
- Integrated healthcare service offerings.
- Strong brand reputation.
- Focus on community-based healthcare solutions.
What Are SGIPF's Weaknesses?
- Limited international presence.
- Dependence on the Japanese market.
- Potential for increased competition.
- Exposure to regulatory changes in the healthcare sector.
What Could Drive SGIPF Stock Higher?
- Expansion of the drugstore network into new geographic areas within Japan.
- Increasing demand for healthcare services due to Japan's aging population.
- Development and launch of new pharmaceutical products and healthcare services.
- Strengthening partnerships with healthcare providers to offer integrated solutions.
What Are the Key Risks for SGIPF?
- Increased competition from other drugstore chains and online retailers.
- Regulatory changes in the healthcare sector could impact profitability.
- Economic downturn in Japan could reduce consumer spending.
- Dependence on the Japanese market exposes the company to regional economic risks.
What Are the Growth Opportunities for SGIPF?
- Expanding the network of drugstores: Sugi Holdings can increase its market share by strategically expanding its network of drugstores in underserved areas of Japan. The Japanese drugstore market is estimated to be worth over $100 billion, providing ample opportunity for growth. By opening new stores and acquiring smaller chains, Sugi Holdings can reach new customers and increase its revenue. This expansion can be achieved within the next 3-5 years.
- Enhancing healthcare service offerings: Sugi Holdings can further differentiate itself by expanding its healthcare service offerings, such as health counseling, home-visit prescription dispensing, and elderly care support. The demand for these services is growing rapidly due to Japan's aging population. By investing in training and technology, Sugi Holdings can provide high-quality healthcare services and attract new customers. This enhancement can be implemented within the next 2-3 years.
- Developing online sales channels: Sugi Holdings can tap into the growing e-commerce market by developing online sales channels for its pharmaceutical products and health-related goods. The online retail market in Japan is estimated to be worth over $200 billion, providing a significant opportunity for growth. By creating a user-friendly online platform and offering convenient delivery options, Sugi Holdings can reach a wider audience and increase its sales. This development can be achieved within the next 1-2 years.
- Strengthening partnerships with healthcare providers: Sugi Holdings can strengthen its partnerships with healthcare providers, such as hospitals and clinics, to provide integrated healthcare solutions to patients. By collaborating with healthcare providers, Sugi Holdings can offer a seamless experience for patients and improve their health outcomes. This collaboration can be established within the next 2-3 years.
- Investing in research and development: Sugi Holdings can invest in research and development to develop new pharmaceutical products and healthcare services. By innovating and creating new solutions, Sugi Holdings can differentiate itself from its competitors and attract new customers. This investment can be made over the next 3-5 years.
What Opportunities Does SGIPF Have?
- Expanding the network of drugstores.
- Enhancing healthcare service offerings.
- Developing online sales channels.
- Strengthening partnerships with healthcare providers.
What Threats Does SGIPF Face?
- Increasing competition from other drugstore chains.
- Regulatory changes in the healthcare sector.
- Economic downturn in Japan.
- Changes in consumer preferences.
What Are SGIPF's Competitive Advantages?
- Established network of approximately 1,483 drugstores across Japan.
- Integrated healthcare service offerings, including health counseling and home-visit prescription dispensing.
- Strong brand reputation and customer loyalty.
- Focus on community-based healthcare solutions.
What Does SGIPF Do?
Founded in 1976 and headquartered in Obu, Japan, Sugi Holdings Co.,Ltd. has evolved into a significant player in the Japanese drugstore market. The company operates approximately 1,483 drugstores across Japan, providing a wide range of pharmaceutical products, over-the-counter medications, and health-related goods. Beyond retail, Sugi Holdings distinguishes itself through its comprehensive healthcare services, including health counseling provided by qualified pharmacists, home-visit prescription dispensing and nursing care for patients with limited mobility, and medical consulting services to address specific health concerns. Sugi Holdings extends its services to support the broader community, offering staff agency services, promoting disabled employment, and providing support for elderly home care. This integrated approach positions Sugi Holdings not just as a retailer but as a healthcare solutions provider deeply embedded in the communities it serves. The company's commitment to these services reflects its focus on addressing the evolving healthcare needs of Japan's aging population and promoting overall well-being.
What Products and Services Does SGIPF Offer?
- Operates a chain of drugstores in Japan.
- Provides pharmaceutical products and over-the-counter medications.
- Offers health counseling services by qualified pharmacists.
- Provides home-visit prescription dispensing and nursing care.
- Offers medical consulting services.
- Provides staff agency services.
- Promotes disabled employment.
- Provides elderly home care support services.
How Does SGIPF Make Money?
- Revenue from the sale of pharmaceutical products and over-the-counter medications.
- Revenue from healthcare services, such as health counseling and home-visit prescription dispensing.
- Revenue from staff agency services.
- Revenue from elderly home care support services.
What Industry Does SGIPF Operate In?
Sugi Holdings operates within the Japanese pharmaceutical retail industry, which is characterized by a large number of drugstore chains and a growing demand for healthcare services. The industry is influenced by Japan's aging population and increasing healthcare costs. Competition is intense, with companies like ANHGY (Tsuruha Holdings) and ARHCF (Matsumotokiyoshi Holdings) vying for market share. Sugi Holdings differentiates itself through its integrated healthcare services, including home-visit prescription dispensing and elderly care support, positioning it to capitalize on the growing demand for community-based healthcare solutions.
Who Are SGIPF's Key Customers?
- Individuals seeking pharmaceutical products and over-the-counter medications.
- Patients requiring health counseling and medical advice.
- Individuals needing home-visit prescription dispensing and nursing care.
- Elderly individuals requiring home care support.
- Healthcare providers seeking staff agency services.
FY2026 estForward Outlook
Wall Street analysts project Sugi Holdings Co.,Ltd. revenue of about $1.01T for fiscal 2026, with EPS near $247.95. The estimate reflects 8 contributing analysts.
SGIPF Valuation & Market Position
With a $3.69B market cap, Sugi Holdings Co.,Ltd. sits in the mid-cap segment of the market.
ROE 16%Key Financial Metrics
Return on equity for Sugi Holdings Co.,Ltd. stands at 16.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.3%, showing how much profit it generates from its asset base. SGIPF trades at a trailing price-to-earnings ratio of 12.58, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Sugi Holdings Co.,Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.10 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Sugi Holdings Co.,Ltd. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Obu, JP. The company is led by CEO Katsunori Sugiura. SGIPF has traded publicly since 2020.
SGIPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in the growth trajectory.
- Community sentiment has been increasingly positive, with discussions highlighting Sugi Holdings' innovative approaches in their sector.
- Market perception has shifted favorably due to recent strategic partnerships that enhance their competitive edge.
- The company's commitment to sustainability aligns with growing consumer preferences, positioning it well for future demand.
Bear Case
- Concerns have emerged about supply chain disruptions affecting operational efficiency, leading to skepticism among investors.
- Social sentiment reflects worries about potential regulatory challenges that could impact business operations in key markets.
- Some analysts express caution due to the overall market volatility, which may affect investor confidence in smaller companies like Sugi Holdings.
- There are mixed reviews regarding the company's recent financial performance, raising doubts about its ability to sustain growth in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SGIPF Latest News
No recent news available for SGIPF.
SGIPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SGIPF.
Price Targets
Wall Street price target analysis for SGIPF.
SGIPF MoonshotScore
What does this score mean?
The MoonshotScore rates SGIPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Katsunori Sugiura
CEO
Katsunori Sugiura is the CEO of Sugi Holdings Co.,Ltd. His background includes extensive experience in the pharmaceutical retail industry. He has been with Sugi Holdings for many years, holding various leadership positions before assuming the role of CEO. His expertise lies in strategic planning, operational management, and business development within the healthcare sector. He is responsible for overseeing the company's overall performance and driving its growth strategy.
Track Record: Under Katsunori Sugiura's leadership, Sugi Holdings has expanded its network of drugstores and enhanced its healthcare service offerings. He has focused on strengthening the company's brand reputation and improving customer satisfaction. Key milestones include the successful integration of acquired businesses and the implementation of new technologies to improve operational efficiency. He has also overseen the development of new online sales channels to reach a wider audience.
SGIPF OTC Market Information
The OTC Other tier, where SGIPF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no reporting requirements, meaning they may not provide regular financial disclosures to the public. This lack of transparency increases the risk for investors, as it can be difficult to assess the company's financial health and performance. Trading on the OTC Other tier is distinct from trading on major exchanges like the NYSE or NASDAQ, which have stricter listing requirements and reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in SGIPF.
- Low trading volume and wide bid-ask spreads can lead to price volatility and illiquidity.
- Potential for fraud or manipulation is higher on the OTC market.
- Lack of regulatory oversight compared to major exchanges.
- Difficulty in obtaining reliable information about the company's operations and financial performance.
- Verify the company's registration and legal status.
- Attempt to obtain financial statements and assess the company's financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity and trading volume of the stock.
- Be aware of the potential risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Established presence in the Japanese drugstore market.
- Integrated healthcare service offerings.
- Operating history since 1976.
- Managing 8724 employees.
Sugi Holdings Co.,Ltd. Healthcare Stock: Key Questions Answered
What does Sugi Holdings Co.,Ltd. do?
Sugi Holdings Co.,Ltd. operates a chain of drugstores in Japan, providing pharmaceutical products, over-the-counter medications, and healthcare-related services. The company differentiates itself through its integrated healthcare service offerings, including health counseling, home-visit prescription dispensing, and elderly care support. Sugi Holdings aims to be a community-based healthcare provider, addressing the evolving needs of Japan's aging population and promoting overall well-being. The company operates approximately 1,483 stores across Japan.
What are the main risks for SGIPF?
The main risks for Sugi Holdings include increasing competition from other drugstore chains and online retailers, regulatory changes in the healthcare sector, and economic downturns in Japan. The company's dependence on the Japanese market also exposes it to regional economic risks. Additionally, the limited financial disclosure associated with trading on the OTC Other tier increases the risk for investors. Investors should carefully consider these risks before investing in SGIPF.
What are the key factors to evaluate for SGIPF?
Evaluate SGIPF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SGIPF data refresh on this page?
SGIPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SGIPF's recent stock price performance?
Sugi Holdings Co.,Ltd. (SGIPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Japanese drugstore market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SGIPF overvalued or undervalued right now?
Valuing Sugi Holdings Co.,Ltd. (SGIPF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SGIPF?
Before investing in Sugi Holdings Co.,Ltd. (SGIPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SGIPF to a portfolio?
Key strength of Sugi Holdings Co.,Ltd. (SGIPF): Established presence in the Japanese drugstore market. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.